PDCD1 and cancer: Thus, the negative regulation of PD-L1 protein levels by the E3 ubiquitin ligase GP78 can enhance cancer immune surveillance and also serve as an alternative biomarker to predict whether cancer patients can benefit from PD-1/PD-L1-based cancer immunotherapies.